Towards a New Paradigm in the Treatment of Parkinson's Disease. SymposiumOERTEL, Wolfgang H.Clinical neuropharmacology. 1997, Vol 20, issn 0362-5664, 48 p., SUP1Conference Proceedings

Oxidative stress in Parkinson's diseaseOLANOW, C. W.Clinical neuropharmacology. 1997, Vol 20, pp S3-S7, issn 0362-5664, SUP1Conference Paper

Attitudes and barriers to clinical practice guidelines in general and to the guideline on Parkinson's disease. A National Survey of German neurologists in private practiceLARISCH, Astrid; OERTEL, Wolfgang H; EGGERT, Karla et al.Journal of neurology. 2009, Vol 256, Num 10, pp 1681-1688, issn 0340-5354, 8 p.Article

Low-dose pramipexole in the management of restless legs syndrome: An open label trialSTIASNY-KOLSTER, Karin; OERTEL, Wolfgang H.Neuropsychobiology. 2004, Vol 50, Num 1, pp 65-70, issn 0302-282X, 6 p.Article

Macrogol 3350/Electrolyte improves constipation in Parkinson's disease and multiple system atrophyEICHHORN, Tobias E; OERTEL, Wolfgang H.Movement disorders. 2001, Vol 16, Num 6, pp 1176-1177, issn 0885-3185Article

New alternatives for the management of early Parkinson's disease (PD) : Pramipexole monotherapy in mild to moderate PD. A review of three studiesSHANNON, K. M.Clinical neuropharmacology. 1997, Vol 20, pp S22-S27, issn 0362-5664, SUP1Conference Paper

Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: Impact of motor fluctuations and dyskinesiasDODEL, Richard C; BERGER, Karin; OERTEL, Wolfgang H et al.PharmacoEconomics (Auckland). 2001, Vol 19, Num 10, pp 1013-1038, issn 1170-7690Article

Does the clinical practice guideline on Parkinson's disease change health outcomes? A cluster randomized controlled trialLARISCH, Astrid; REUSS, Alexander; OERTEL, Wolfgang H et al.Journal of neurology. 2011, Vol 258, Num 5, pp 826-834, issn 0340-5354, 9 p.Article

The case for neuroprotection with dopamine agonistsCARVEY, P. M; LING, Z.-D.Clinical neuropharmacology. 1997, Vol 20, pp S8-S21, issn 0362-5664, SUP1Conference Paper

Update on restless legs syndromeTRENKWALDER, Claudia; OERTEL, Wolfgang H; ALLEN, Richard et al.Movement disorders. 2007, Vol 22, issn 0885-3185, 114 p., SUP18Serial Issue

A non-ergot dopamine agonist, pramipexole, in the therapy of advanced Parkinson's disease : Improvement of Parkinsonian symptoms and treatment-associated complications. A review of three studiesPOGARELL, O; KÜNIG, G; OERTEL, W. H et al.Clinical neuropharmacology. 1997, Vol 20, pp S28-S35, issn 0362-5664, SUP1Conference Paper

The development of dopamine overflow from foetal nigral grafts in the intact rat striatum and their influence on contralateral striatal dopamine overflowEARL, Christopher D; MARBURGER, Andrea; SAUTTER, Jiirgen et al.Neurochemistry international. 2001, Vol 39, Num 2, pp 161-167, issn 0197-0186Article

Long-term efficacy and safety of pramipexole in advanced Parkinson's disease : Results from a European multicenter trialMÖLLER, J. Carsten; OERTEL, Wolfgang H; KOSTER, Jürgen et al.Movement disorders. 2005, Vol 20, Num 5, pp 602-610, issn 0885-3185, 9 p.Article

Validation of the L-DOPA test for diagnosis of restless legs syndromeSTIASNY-KOLSTER, Karin; KOHNEN, Ralf; MOLLER, Jens Carsten et al.Movement disorders. 2006, Vol 21, Num 9, pp 1333-1339, issn 0885-3185, 7 p.Article

Steele-Richardson-Olszewski syndrome: Reduction of dopamine D₂ receptor binding relates to the severity of midbrain atrophy in vivo: ¹²³IBZM SPECT and MRI studyARNOLD, Guy; TATSCH, Klaus; KRAFT, Eduardo et al.Movement disorders. 2002, Vol 17, Num 3, pp 557-562, issn 0885-3185Article

Myoclonic encephalopathy caused by chronic bismuth abuseTEEPKER, Michael; HAMER, Hajo M; KNAKE, Susanne et al.Epileptic disorders. 2002, Vol 4, Num 4, pp 229-233, issn 1294-9361, 5 p.Article

New approaches to dissect degeneracy and specificity in T cell antigen recognitionJACOBSEN, Marc; CEPOK, Sabine; OERTEL, Wolfgang H et al.Journal of molecular medicine (Berlin. Print). 2001, Vol 79, Num 7, pp 358-367, issn 0946-2716Article

Hyperalgesia and functional sensory loss in restless legs syndromeSTIASNY-KOLSTER, Karin; PFAU, Doreen B; OERTEL, Wolfgang H et al.Pain (Amsterdam). 2013, Vol 154, Num 8, pp 1457-1463, issn 0304-3959, 7 p.Article

The PLA2G6 Gene in Early-Onset Parkinson's DiseaseKAUTHER, Kai Michael; HÖFT, Christine; RISSLING, Ida et al.Movement disorders. 2011, Vol 26, Num 13, pp 2415-2417, issn 0885-3185, 3 p.Article

Reduced genital sensitivity in female patients with multiple system atrophy of parkinsonian typeOERTEL, Wolfgang H; WÄCHTER, Tobias; QUINN, Niall P et al.Movement disorders. 2003, Vol 18, Num 4, pp 430-432, issn 0885-3185, 3 p.Article

Pain Sensitivity and Clinical Progression in Parkinson's DiseaseMYLIUS, Veit; BREBBERMANN, Juliane; DOHMANN, Helena et al.Movement disorders. 2011, Vol 26, Num 12, pp 2220-2225, issn 0885-3185, 6 p.Article

RLS Epidemiology-Frequencies, Risk Factors and Methods in Population StudiesBERGER, Klaus; KURTH, Tobias.Movement disorders. 2007, Vol 22, issn 0885-3185, S420-S423, SUP18Article

Cost Effectiveness of Pharmacotherapies in Early Parkinson's DiseaseEGGERT, Karla M; REESE, Jens P; OERTEL, Wolfgang H et al.CNS drugs. 2008, Vol 22, Num 10, pp 841-860, issn 1172-7047, 20 p.Article

State of the Art in Restless Legs Syndrome Therapy : Practice Recommendations for Treating Restless Legs SyndromeOERTEL, Wolfgang H; TRENKWALDER, Claudia; ZUCCONI, Marco et al.Movement disorders. 2007, Vol 22, issn 0885-3185, S466-S475, SUP18Article

Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patientsSELTER, Rebecca C; BIBERACHER, Viola; GRUMMEL, Verena et al.Multiple sclerosis. 2013, Vol 19, Num 11, pp 1454-1461, issn 1352-4585, 8 p.Article